Ebola virus disease in humans: Pathophysiology and immunity

Current Topics in Microbiology and Immunology

Volumn 411, Issue , 2017, Pages 141-169

  Muñoz Fontela, César ^a   McElroy, Anita K ^b  

^a LEIBNIZ INSTITUTE FOR EXPERIMENTAL VIROLOGY   (Germany)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; CD16 ANTIGEN; CD38 ANTIGEN; CD4 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; HLA DR ANTIGEN; IMMUNOGLOBULIN G; NEUTRALIZING ANTIBODY; THROMBOMODULIN; VIRUS ANTIBODY; VON WILLEBRAND FACTOR;

ADAPTIVE IMMUNITY; AGE; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY RESPONSE; ANTIGEN PRESENTATION; BLOOD CLOTTING DISORDER; BLOOD VESSEL PERMEABILITY; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; COMORBIDITY; DENDRITIC CELL; DOWN REGULATION; EBOLA HEMORRHAGIC FEVER; EBOLAVIRUS; ELECTROLYTE DISTURBANCE; ENDOTHELIAL DYSFUNCTION; EPIDEMIC; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGICAL MEMORY; MACROPHAGE; MALARIA; MIXED INFECTION; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; VIRAL CLEARANCE; VIRUS ENTRY; VIRUS REPLICATION; VIRUS TRANSMISSION; AFRICA; IMMUNOLOGY; VIROLOGY;

AFRICA, WESTERN; DISEASE OUTBREAKS; EBOLAVIRUS; HEMORRHAGIC FEVER, EBOLA; HUMANS;

EID: 85039416307     PISSN: 0070217X     EISSN: 21969965     Source Type: Book Series    
DOI: 10.1007/82_2017_11     Document Type: Chapter

References (166)

1. Adjemian J, Farnon EC, Tschioko F, Wamala JF, Byaruhanga E, Bwire GS, Kansiime E, Kagirita A, Ahimbisibwe S, Katunguka F, Jeffs B, Lutwama JJ, Downing R, Tappero JW, Formenty P, Amman B, Manning C, Towner J, Nichol ST, Rollin PE (2011) Outbreak of Marburg hemorrhagic fever among miners in Kamwenge and Ibanda Districts, Uganda, 2007. J Infect Dis 204(Suppl 3):S796–799. doi:10.1093/infdis/jir312.
2. Agnandji ST, Huttner A, Zinser ME, Njuguna P, Dahlke C, Fernandes JF, Yerly S, Dayer JA, Kraehling V, Kasonta R, Adegnika AA, Altfeld M, Auderset F, Bache EB, Biedenkopf N, Borregaard S, Brosnahan JS, Burrow R, Combescure C, Desmeules J, Eickmann M, Fehling SK, Finckh A, Goncalves AR, Grobusch MP, Hooper J, Jambrecina A, Kabwende AL, Kaya G, Kimani D, Lell B, Lemaitre B, Lohse AW, Massinga-Loembe M, Matthey A, Mordmuller B, Nolting A, Ogwang C, Ramharter M, Schmidt-Chanasit J, Schmiedel S, Silvera P, Stahl FR, Staines HM, Strecker T, Stubbe HC, Tsofa B, Zaki S, Fast P, Moorthy V, Kaiser L, Krishna S, Becker S, Kieny MP, Bejon P, Kremsner PG, Addo MM, Siegrist CA (2016) Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe. N Engl J Med 374(17):1647–1660. doi:10.1056/NEJMoa1502924.
3. Alvarez CP, Lasala F, Carrillo J, Muniz O, Corbi AL, Delgado R (2002) C-type lectins DC-SIGN and L-SIGN mediate cellular entry by Ebola virus in cis and in trans. J Virol 76(13):6841–6844.
4. Amman BR, Carroll SA, Reed ZD, Sealy TK, Balinandi S, Swanepoel R, Kemp A, Erickson BR, Comer JA, Campbell S, Cannon DL, Khristova ML, Atimnedi P, Paddock CD, Crockett RJ, Flietstra TD, Warfield KL, Unfer R, Katongole-Mbidde E, Downing R, Tappero JW, Zaki SR, Rollin PE, Ksiazek TG, Nichol ST, Towner JS (2012) Seasonal pulses of Marburg virus circulation in juvenile Rousettus aegyptiacus bats coincide with periods of increased risk of human infection. PLoS Pathog 8(10):e1002877. doi:10.1371/journal.ppat.1002877.
5. Appay V, Dunbar PR, Callan M, Klenerman P, Gillespie GM, Papagno L, Ogg GS, King A, Lechner F, Spina CA, Little S, Havlir DV, Richman DD, Gruener N, Pape G, Waters A, Easterbrook P, Salio M, Cerundolo V, McMichael AJ, Rowland-Jones SL (2002) Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nat Med 8(4):379–385. doi:10.1038/nm0402-379.
6. Auffray C, Fogg D, Garfa M, Elain G, Join-Lambert O, Kayal S, Sarnacki S, Cumano A, Lauvau G, Geissmann F (2007) Monitoring of blood vessels and tissues by a population of monocytes with patrolling behavior. Science 317(5838):666–670. doi:10.1126/science.1142883.
7. Bah EI, Lamah MC, Fletcher T, Jacob ST, Brett-Major DM, Sall AA, Shindo N, Fischer WA 2nd, Lamontagne F, Saliou SM, Bausch DG, Moumie B, Jagatic T, Sprecher A, Lawler JV, Mayet T, Jacquerioz FA, Mendez Baggi MF, Vallenas C, Clement C, Mardel S, Faye O, Faye O, Soropogui B, Magassouba N, Koivogui L, Pinto R, Fowler RA (2015) Clinical presentation of patients with Ebola virus disease in Conakry, Guinea. N Engl J Med 372(1):40–47. doi:10.1056/NEJMoa1411249.
8. Baize S, Leroy EM, Georges AJ, Georges-Courbot MC, Capron M, Bedjabaga I, Lansoud-Soukate J, Mavoungou E (2002) Inflammatory responses in Ebola virus-infected patients. Clin Exp Immunol 128(1):163–168.
9. Baize S, Leroy EM, Georges-Courbot MC, Capron M, Lansoud-Soukate J, Debre P, Fisher-Hoch SP, McCormick JB, Georges AJ (1999) Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients. Nat Med 5(4):423–426. doi:10.1038/7422.
10. Banchereau J, Steinman RM (1998) Dendritic cells and the control of immunity. Nature 392(6673):245–252. doi:10.1038/32588.
11. Barry M, Traore FA, Sako FB, Kpamy DO, Bah EI, Poncin M, Keita S, Cisse M, Toure A (2014) Ebola outbreak in Conakry, Guinea: epidemiological, clinical, and outcome features. Med Mal Infect 44(11–12):491–494. doi:10.1016/j.medmal.2014.09.009.
12. Bausch DG, Borchert M, Grein T, Roth C, Swanepoel R, Libande ML, Talarmin A, Bertherat E, Muyembe-Tamfum JJ, Tugume B, Colebunders R, Konde KM, Pirad P, Olinda LL, Rodier GR, Campbell P, Tomori O, Ksiazek TG, Rollin PE (2003) Risk factors for Marburg hemorrhagic fever, Democratic Republic of the Congo. Emerg Infect Dis 9(12):1531–1537. doi:10.3201/eid0912.030355.
13. Bausch DG, Towner JS, Dowell SF, Kaducu F, Lukwiya M, Sanchez A, Nichol ST, Ksiazek TG, Rollin PE (2007) Assessment of the risk of Ebola virus transmission from bodily fluids and fomites. J Infect Dis 196(Suppl 2):S142–147. doi:10.1086/520545.
14. Bornholdt ZA, Ndungo E, Fusco ML, Bale S, Flyak AI, Crowe JE Jr, Chandran K, Saphire EO (2016a) Host-primed Ebola Virus GP exposes a hydrophobic NPC1 receptor-binding pocket, revealing a target for broadly neutralizing antibodies. mBio 7(1):e02154–02115. doi:10.1128/mBio.02154-15.
15. Bornholdt ZA, Turner HL, Murin CD, Li W, Sok D, Souders CA, Piper AE, Goff A, Shamblin JD, Wollen SE, Sprague TR, Fusco ML, Pommert KB, Cavacini LA, Smith HL, Klempner M, Reimann KA, Krauland E, Gerngross TU, Wittrup KD, Saphire EO, Burton DR, Glass PJ, Ward AB, Walker LM (2016b) Isolation of potent neutralizing antibodies from a survivor of the 2014 Ebola virus outbreak. Science 351(6277):1078–1083. doi:10.1126/science.aad5788.
16. Bosio CM, Aman MJ, Grogan C, Hogan R, Ruthel G, Negley D, Mohamadzadeh M, Bavari S, Schmaljohn A (2003) Ebola and Marburg viruses replicate in monocyte-derived dendritic cells without inducing the production of cytokines and full maturation. J Infect Dis 188(11):1630–1638. doi:10.1086/379199.
17. Bower H, Johnson S, Bangura MS, Kamara AJ, Kamara O, Mansaray SH, Sesay D, Turay C, Checchi F, Glynn JR (2016) Exposure-specific and age-specific attack rates for Ebola Virus disease in Ebola-affected households, Sierra Leone. Emerg Infect Dis 22(8). doi:10.3201/eid2208.160163.
18. Brannan JM, Froude JW, Prugar LI, Bakken RR, Zak SE, Daye SP, Wilhelmsen CE, Dye JM (2015) Interferon alpha/beta receptor-deficient mice as a model for Ebola Virus disease. J Infect Dis 212(Suppl 2):S282–294. doi:10.1093/infdis/jiv215.
19. Bray M, Raymond JL, Geisbert T, Baker RO (2002) 3-deazaneplanocin A induces massively increased interferon-alpha production in Ebola virus-infected mice. Antiviral Res 55(1):151–159.
20. Buchbinder EI, Desai A (2016) CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition. Am J Clin Oncol 39(1):98–106. doi:10.1097/COC.0000000000000239.
21. Bwaka MA, Bonnet MJ, Calain P, Colebunders R, De Roo A, Guimard Y, Katwiki KR, Kibadi K, Kipasa MA, Kuvula KJ, Mapanda BB, Massamba M, Mupapa KD, Muyembe-Tamfum JJ, Ndaberey E, Peters CJ, Rollin PE, Van den Enden E, Van den Enden E (1999) Ebola hemorrhagic fever in Kikwit, Democratic Republic of the Congo: clinical observations in 103 patients. J Infect Dis 179(Suppl 1):S1–7. doi:10.1086/514308.
22. Carrion R Jr, Brasky K, Mansfield K, Johnson C, Gonzales M, Ticer A, Lukashevich I, Tardif S, Patterson J (2007) Lassa virus infection in experimentally infected marmosets: liver pathology and immunophenotypic alterations in target tissues. J Virol 81(12):6482–6490. doi:10.1128/JVI.02876-06.
23. Centers for Disease C, Prevention (2009) Imported case of Marburg hemorrhagic fever—Colorado, 2008. MMWR Morb Mortal Wkly Rep 58(49):1377–1381.
24. Chertow DS, Kleine C, Edwards JK, Scaini R, Giuliani R, Sprecher A (2014) Ebola virus disease in West Africa–clinical manifestations and management. N Engl J Med 371(22):2054–2057. doi:10.1056/NEJMp1413084.
25. Chughtai AA, Barnes M, Macintyre CR (2016) Persistence of Ebola virus in various body fluids during convalescence: evidence and implications for disease transmission and control. Epidemiol Infect 144(8):1652–1660. doi:10.1017/S0950268816000054.
26. Clark DV, Kibuuka H, Millard M, Wakabi S, Lukwago L, Taylor A, Eller MA, Eller LA, Michael NL, Honko AN, Olinger GG Jr, Schoepp RJ, Hepburn MJ, Hensley LE, Robb ML (2015) Long-term sequelae after Ebola virus disease in Bundibugyo, Uganda: a retrospective cohort study. Lancet Infect Dis 15(8):905–912. doi:10.1016/S1473-3099(15)70152-0.
27. Colebunders R, Tshomba A, Van Kerkhove MD, Bausch DG, Campbell P, Libande M, Pirard P, Tshioko F, Mardel S, Mulangu S, Sleurs H, Rollin PE, Muyembe-Tamfum JJ, Jeffs B, Borchert M, International S, Technical Committee DRCWDMOIG (2007) Marburg hemorrhagic fever in Durba and Watsa, Democratic Republic of the Congo: clinical documentation, features of illness, and treatment. J Infect Dis 196(Suppl 2):S148–153. doi:10.1086/520543.
28. Corti D, Misasi J, Mulangu S, Stanley DA, Kanekiyo M, Wollen S, Ploquin A, Doria-Rose NA, Staupe RP, Bailey M, Shi W, Choe M, Marcus H, Thompson EA, Cagigi A, Silacci C, Fernandez-Rodriguez B, Perez L, Sallusto F, Vanzetta F, Agatic G, Cameroni E, Kisalu N, Gordon I, Ledgerwood JE, Mascola JR, Graham BS, Muyembe-Tamfun JJ, Trefry JC, Lanzavecchia A, Sullivan NJ (2016) Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody. Science 351(6279):1339–1342. doi:10.1126/science.aad5224.
29. Cros J, Cagnard N, Woollard K, Patey N, Zhang SY, Senechal B, Puel A, Biswas SK, Moshous D, Picard C, Jais JP, D’Cruz D, Casanova JL, Trouillet C, Geissmann F (2010) Human CD14dim monocytes patrol and sense nucleic acids and viruses via TLR7 and TLR8 receptors. Immunity 33(3):375–386. doi:10.1016/j.immuni.2010.08.012.
30. Cusi MG, Gandolfo C, Terrosi C, Gori Savellini G, Belmonte G, Miracco C (2016) Toscana virus infects dendritic and endothelial cells opening the way for the nervous system. J Neurovirol 22(3):307–315. doi:10.1007/s13365-015-0395-2.
31. Dallatomasina S, Crestani R, Sylvester Squire J, Declerk H, Caleo GM, Wolz A, Stinson K, Patten G, Brechard R, Gbabai OB, Spreicher A, Van Herp M, Zachariah R (2015) Ebola outbreak in rural West Africa: epidemiology, clinical features and outcomes. Trop Med Int Health TM & IH 20(4):448–454. doi:10.1111/tmi.12454.
32. Deen GF, Knust B, Broutet N, Sesay FR, Formenty P, Ross C, Thorson AE, Massaquoi TA, Marrinan JE, Ervin E, Jambai A, McDonald SL, Bernstein K, Wurie AH, Dumbuya MS, Abad N, Idriss B, Wi T, Bennett SD, Davies T, Ebrahim FK, Meites E, Naidoo D, Smith S, Banerjee A, Erickson BR, Brault A, Durski KN, Winter J, Sealy T, Nichol ST, Lamunu M, Stroher U, Morgan O, Sahr F (2015) Ebola RNA Persistence in Semen of Ebola Virus disease survivors—preliminary report. N Engl J Med. doi:10.1056/NEJMoa1511410.
33. Dowell SF (1996) Ebola hemorrhagic fever: why were children spared? Pediatr Infect Dis J 15(3):189–191.
34. Dowell SF, Mukunu R, Ksiazek TG, Khan AS, Rollin PE, Peters CJ (1999) Transmission of Ebola hemorrhagic fever: a study of risk factors in family members, Kikwit, Democratic Republic of the Congo, 1995. Commission de Lutte contre les Epidemies a Kikwit. J Infect Dis 179(Suppl 1):S87–91. doi:10.1086/514284.
35. Ebihara H, Rockx B, Marzi A, Feldmann F, Haddock E, Brining D, LaCasse RA, Gardner D, Feldmann H (2011) Host response dynamics following lethal infection of rhesus macaques with Zaire ebolavirus. J Infect Dis 204(Suppl 3):S991–999. doi:10.1093/infdis/jir336.
36. Ebola haemorrhagic fever in Zaire. (1976/1978). Bulletin of the World Health Organization 56 (2):271–293.
37. Emond RT, Evans B, Bowen ET, Lloyd G (1977) A case of Ebola virus infection. Br Med J 2(6086):541–544.
38. Ersland K, Wuthrich M, Klein BS (2010) Dynamic interplay among monocyte-derived, dermal, and resident lymph node dendritic cells during the generation of vaccine immunity to fungi. Cell Host Microbe 7(6):474–487. doi:10.1016/j.chom.2010.05.010.
39. Escudero-Perez B, Volchkova VA, Dolnik O, Lawrence P, Volchkov VE (2014) Shed GP of Ebola virus triggers immune activation and increased vascular permeability. PLoS Pathog 10(11):e1004509. doi:10.1371/journal.ppat.1004509.
40. Ewer K, Rampling T, Venkatraman N, Bowyer G, Wright D, Lambe T, Imoukhuede EB, Payne R, Fehling SK, Strecker T, Biedenkopf N, Krahling V, Tully CM, Edwards NJ, Bentley EM, Samuel D, Labbe G, Jin J, Gibani M, Minhinnick A, Wilkie M, Poulton I, Lella N, Roberts R, Hartnell F, Bliss C, Sierra-Davidson K, Powlson J, Berrie E, Tedder R, Roman F, De Ryck I, Nicosia A, Sullivan NJ, Stanley DA, Mbaya OT, Ledgerwood JE, Schwartz RM, Siani L, Colloca S, Folgori A, Di Marco S, Cortese R, Wright E, Becker S, Graham BS, Koup RA, Levine MM, Volkmann A, Chaplin P, Pollard AJ, Draper SJ, Ballou WR, Lawrie A, Gilbert SC, Hill AV (2016) A monovalent Chimpanzee Adenovirus Ebola Vaccine boosted with MVA. N Engl J Med 374(17):1635–1646. doi:10.1056/NEJMoa1411627.
41. Faye O, Andronico A, Faye O, Salje H, Boelle PY, Magassouba N, Bah EI, Koivogui L, Diallo B, Diallo AA, Keita S, Konde MK, Fowler R, Fall G, Cauchemez S, Sall AA (2015) Use of Viremia to evaluate the baseline case fatality ratio of Ebola Virus disease and inform treatment studies: a retrospective cohort study. PLoS Med 12(12):e1001908. doi:10.1371/journal.pmed.1001908.
42. Feldmann H, Bugany H, Mahner F, Klenk HD, Drenckhahn D, Schnittler HJ (1996) Filovirus-induced endothelial leakage triggered by infected monocytes/macrophages. J Virol 70(4):2208–2214.
43. Feldmann H, Geisbert TW (2011) Ebola haemorrhagic fever. Lancet 377(9768):849–862. doi:10.1016/S0140-6736(10)60667-8.
44. Fischer RJ, Judson S, Miazgowicz K, Bushmaker T, Munster VJ (2016) Ebola Virus persistence in Semen Ex Vivo. Emerg Infect Dis 22(2):289–291. doi:10.3201/eid2202.151278.
45. Fisher-Hoch SP, Platt GS, Neild GH, Southee T, Baskerville A, Raymond RT, Lloyd G, Simpson DI (1985) Pathophysiology of shock and hemorrhage in a fulminating viral infection (Ebola). J Infect Dis 152(5):887–894.
46. Francesconi P, Yoti Z, Declich S, Onek PA, Fabiani M, Olango J, Andraghetti R, Rollin PE, Opira C, Greco D, Salmaso S (2003) Ebola hemorrhagic fever transmission and risk factors of contacts, Uganda. Emerg Infect Dis 9(11):1430–1437. doi:10.3201/eid0911.030339.
47. Fujinami RS, von Herrath MG, Christen U, Whitton JL (2006) Molecular mimicry, bystander activation, or viral persistence: infections and autoimmune disease. Clin Microbiol Rev 19(1):80–94. doi:10.1128/CMR.19.1.80-94.2006.
48. Gear JS, Cassel GA, Gear AJ, Trappler B, Clausen L, Meyers AM, Kew MC, Bothwell TH, Sher R, Miller GB, Schneider J, Koornhof HJ, Gomperts ED, Isaacson M, Gear JH (1975) Outbreake of Marburg virus disease in Johannesburg. Br Med J 4(5995):489–493.
49. Geisbert TW, Hensley LE, Larsen T, Young HA, Reed DS, Geisbert JB, Scott DP, Kagan E, Jahrling PB, Davis KJ (2003a) Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection. Am J Pathol 163(6):2347–2370. doi:10.1016/S0002-9440(10)63591-2.
50. Geisbert TW, Young HA, Jahrling PB, Davis KJ, Kagan E, Hensley LE (2003b) Mechanisms underlying coagulation abnormalities in ebola hemorrhagic fever: overexpression of tissue factor in primate monocytes/macrophages is a key event. J Infect Dis 188(11):1618–1629. doi:10.1086/379724.
51. Geisbert TW, Young HA, Jahrling PB, Davis KJ, Larsen T, Kagan E, Hensley LE (2003c) Pathogenesis of Ebola hemorrhagic fever in primate models: evidence that hemorrhage is not a direct effect of virus-induced cytolysis of endothelial cells. Am J Pathol 163(6):2371–2382. doi:10.1016/S0002-9440(10)63592-4.
52. Gignoux E, Azman AS, de Smet M, Azuma P, Massaquoi M, Job D, Tiffany A, Petrucci R, Sterk E, Potet J, Suzuki M, Kurth A, Cannas A, Bocquin A, Strecker T, Logue C, Pottage T, Yue C, Cabrol JC, Serafini M, Ciglenecki I (2016) Effect of Artesunate-Amodiaquine on mortality related to Ebola Virus disease. N Engl J Med 374(1):23–32. doi:10.1056/NEJMoa1504605.
53. Green E, Hunt L, Ross JC, Nissen NM, Curran T, Badhan A, Sutherland KA, Richards J, Lee JS, Allen SH, Laird S, Blackman M, Collacott I, Parker PA, Walbridge A, Phillips R, Sellu SJ, Dama A, Sheriff AK, Zombo J, Ngegba D, Wurie AH, Checchi F, Brooks TJ (2016) Viraemia and Ebola virus secretion in survivors of Ebola virus disease in Sierra Leone: a cross-sectional cohort study. Lancet Infect Dis. doi:10.1016/S1473-3099(16)30060-3.
54. Gupta M, MacNeil A, Reed ZD, Rollin PE, Spiropoulou CF (2012) Serology and cytokine profiles in patients infected with the newly discovered Bundibugyo ebolavirus. Virology 423(2):119–124. doi:10.1016/j.virol.2011.11.027.
55. Gupta M, Mahanty S, Ahmed R, Rollin PE (2001) Monocyte-derived human macrophages and peripheral blood mononuclear cells infected with ebola virus secrete MIP-1alpha and TNF-alpha and inhibit poly-IC-induced IFN-alpha in vitro. Virology 284(1):20–25. doi:10.1006/viro.2001.0836.
56. Gupta M, Spiropoulou C, Rollin PE (2007) Ebola virus infection of human PBMCs causes massive death of macrophages, CD4 and CD8 T cell sub-populations in vitro. Virology 364(1):45–54. doi:10.1016/j.virol.2007.02.017.
57. Haniffa M, Collin M, Ginhoux F (2013) Ontogeny and functional specialization of dendritic cells in human and mouse. Adv Immunol 120:1–49. doi:10.1016/B978-0-12-417028-5.00001-6.
58. Henn V, Steinbach S, Buchner K, Presek P, Kroczek RA (2001) The inflammatory action of CD40 ligand (CD154) expressed on activated human platelets is temporally limited by coexpressed CD40. Blood 98(4):1047–1054.
59. Hoarau JJ, Jaffar Bandjee MC, Krejbich Trotot P, Das T, Li-Pat-Yuen G, Dassa B, Denizot M, Guichard E, Ribera A, Henni T, Tallet F, Moiton MP, Gauzere BA, Bruniquet S, Jaffar Bandjee Z, Morbidelli P, Martigny G, Jolivet M, Gay F, Grandadam M, Tolou H, Vieillard V, Debre P, Autran B, Gasque P (2010) Persistent chronic inflammation and infection by Chikungunya arthritogenic alphavirus in spite of a robust host immune response. J Immunol 184(10):5914–5927. doi:10.4049/jimmunol.0900255.
60. Huang YW, Dryman BA, Li W, Meng XJ (2009) Porcine DC-SIGN: molecular cloning, gene structure, tissue distribution and binding characteristics. Dev Comp Immunol 33(4):464–480. doi:10.1016/j.dci.2008.09.010.
61. Hunt BJ (2014) Bleeding and coagulopathies in critical care. N Engl J Med 370(22):2153. doi:10.1056/NEJMc1403768.
62. Hunt L, Gupta-Wright A, Simms V, Tamba F, Knott V, Tamba K, Heisenberg-Mansaray S, Tamba E, Sheriff A, Conteh S, Smith T, Tobin S, Brooks T, Houlihan C, Cummings R, Fletcher T (2015) Clinical presentation, biochemical, and haematological parameters and their association with outcome in patients with Ebola virus disease: an observational cohort study. Lancet Infect Dis 15(11):1292–1299. doi:10.1016/S1473-3099(15)00144-9.
63. Hutchinson KL, Rollin PE (2007) Cytokine and chemokine expression in humans infected with Sudan Ebola virus. J Infect Dis 196(Suppl 2):S357–363. doi:10.1086/520611.
64. Ilinykh PA, Lubaki NM, Widen SG, Renn LA, Theisen TC, Rabin RL, Wood TG, Bukreyev A (2015) Different temporal effects of Ebola Virus VP35 and VP24 proteins on global gene expression in human dendritic cells. J Virol 89(15):7567–7583. doi:10.1128/JVI.00924-15.
65. Jacobs M, Rodger A, Bell DJ, Bhagani S, Cropley I, Filipe A, Gifford RJ, Hopkins S, Hughes J, Jabeen F, Johannessen I, Karageorgopoulos D, Lackenby A, Lester R, Liu RS, MacConnachie A, Mahungu T, Martin D, Marshall N, Mepham S, Orton R, Palmarini M, Patel M, Perry C, Peters SE, Porter D, Ritchie D, Ritchie ND, Seaton RA, Sreenu VB, Templeton K, Warren S, Wilkie GS, Zambon M, Gopal R, Thomson EC (2016) Late Ebola virus relapse causing meningoencephalitis: a case report. Lancet. doi:10.1016/S0140-6736(16)30386-5.
66. Jin H, Yan Z, Prabhakar BS, Feng Z, Ma Y, Verpooten D, Ganesh B, He B (2010) The VP35 protein of Ebola virus impairs dendritic cell maturation induced by virus and lipopolysaccharide. J Gen Virol 91(Pt 2):352–361. doi:10.1099/vir.0.017343-0.
67. Klechevsky E, Banchereau J (2013) Human dendritic cells subsets as targets and vectors for therapy. Ann N Y Acad Sci 1284:24–30. doi:10.1111/nyas.12113.
68. Kondratowicz AS, Lennemann NJ, Sinn PL, Davey RA, Hunt CL, Moller-Tank S, Meyerholz DK, Rennert P, Mullins RF, Brindley M, Sandersfeld LM, Quinn K, Weller M, McCray PB Jr, Chiorini J, Maury W (2011) T-cell immunoglobulin and mucin domain 1 (TIM-1) is a receptor for Zaire Ebolavirus and Lake Victoria Marburgvirus. Proc Natl Acad Sci U S A 108(20):8426–8431. doi:10.1073/pnas.1019030108.
69. Kornbluth RS, Bot A (2012) In this issue: harnessing immunity against difficult targets, through the CD40-CD40L pathway. Int Rev Immunol 31(4):243–245. doi:10.3109/08830185.2012.702511.
70. Kreuels B, Wichmann D, Emmerich P, Schmidt-Chanasit J, de Heer G, Kluge S, Sow A, Renne T, Gunther S, Lohse AW, Addo MM, Schmiedel S (2014) A case of severe Ebola virus infection complicated by gram-negative septicemia. N Engl J Med 371(25):2394–2401. doi:10.1056/NEJMoa1411677.
71. Ksiazek TG, Rollin PE, Williams AJ, Bressler DS, Martin ML, Swanepoel R, Burt FJ, Leman PA, Khan AS, Rowe AK, Mukunu R, Sanchez A, Peters CJ (1999) Clinical virology of Ebola hemorrhagic fever (EHF): virus, virus antigen, and IgG and IgM antibody findings among EHF patients in Kikwit, Democratic Republic of the Congo, 1995. J Infect Dis 179(Suppl 1):S177–187. doi:10.1086/514321.
72. Kvale EO, Dalgaard J, Lund-Johansen F, Rollag H, Farkas L, Midtvedt K, Jahnsen FL, Brinchmann JE, Olweus J (2006) CD11c+ dendritic cells and plasmacytoid DCs are activated by human cytomegalovirus and retain efficient T cell-stimulatory capability upon infection. Blood 107(5):2022–2029. doi:10.1182/blood-2005-05-2016.
73. Lado M, Walker NF, Baker P, Haroon S, Brown CS, Youkee D, Studd N, Kessete Q, Maini R, Boyles T, Hanciles E, Wurie A, Kamara TB, Johnson O, Leather AJ (2015) Clinical features of patients isolated for suspected Ebola virus disease at Connaught Hospital, Freetown, Sierra Leone: a retrospective cohort study. Lancet Infect Dis 15(9):1024–1033. doi:10.1016/S1473-3099(15)00137-1.
74. Langdown J, Luddington RJ, Huntington JA, Baglin TP (2014) A hereditary bleeding disorder resulting from a premature stop codon in thrombomodulin (p.Cys537Stop). Blood 124(12):1951–1956. doi:10.1182/blood-2014-02-557538.
75. Lanini S, Portella G, Vairo F, Kobinger GP, Pesenti A, Langer M, Kabia S, Brogiato G, Amone J, Castilletti C, Miccio R, Zumla A, Capobianchi MR, Di Caro A, Strada G, Ippolito G, Group I-EESLS (2015) Blood kinetics of Ebola virus in survivors and nonsurvivors. J Clin Invest 125(12):4692–4698. doi:10.1172/JCI83111.
76. Lauck M, Bailey AL, Andersen KG, Goldberg TL, Sabeti PC, O’Connor DH (2015) GB virus C coinfections in west African Ebola patients. J Virol 89(4):2425–2429. doi:10.1128/JVI.02752-14.
77. Leon B, Lopez-Bravo M, Ardavin C (2007) Monocyte-derived dendritic cells formed at the infection site control the induction of protective T helper 1 responses against Leishmania. Immunity 26(4):519–531. doi:10.1016/j.immuni.2007.01.017.
78. Leroy EM, Baize S, Debre P, Lansoud-Soukate J, Mavoungou E (2001) Early immune responses accompanying human asymptomatic Ebola infections. Clin Exp Immunol 124(3):453–460.
79. Leroy EM, Baize S, Volchkov VE, Fisher-Hoch SP, Georges-Courbot MC, Lansoud-Soukate J, Capron M, Debre P, McCormick JB, Georges AJ (2000) Human asymptomatic Ebola infection and strong inflammatory response. Lancet 355(9222):2210–2215.
80. Leroy EM, Epelboin A, Mondonge V, Pourrut X, Gonzalez JP, Muyembe-Tamfum JJ, Formenty P (2009) Human Ebola outbreak resulting from direct exposure to fruit bats in Luebo, Democratic Republic of Congo, 2007. Vector Borne Zoonotic Dis 9(6):723–728. doi:10.1089/vbz.2008.0167.
81. Leung LW, Martinez O, Reynard O, Volchkov VE, Basler CF (2011) Ebola virus failure to stimulate plasmacytoid dendritic cell interferon responses correlates with impaired cellular entry. J Infect Dis 204(Suppl 3):S973–977. doi:10.1093/infdis/jir331.
82. Levi M, Toh CH, Thachil J, Watson HG (2009) Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for standards in haematology. Br J Haematol 145(1):24–33. doi:10.1111/j.1365-2141.2009.07600.x.
83. Li J, Duan HJ, Chen HY, Ji YJ, Zhang X, Rong YH, Xu Z, Sun LJ, Zhang JY, Liu LM, Jin B, Zhang J, Du N, Su HB, Teng GJ, Yuan Y, Qin EQ, Jia HJ, Wang S, Guo TS, Wang Y, Mu JS, Yan T, Li ZW, Dong Z, Nie WM, Jiang TJ, Li C, Gao XD, Ji D, Zhuang YJ, Li L, Wang LF, Li WG, Duan XZ, Lu YY, Sun ZQ, Kanu AB, Koroma SM, Zhao M, Ji JS, Wang FS (2016) Age and Ebola viral load correlate with mortality and survival time in 288 Ebola virus disease patients. Int J Infect Dis IJID Official Publ Int Soc Infect Dis 42:34–39. doi:10.1016/j.ijid.2015.10.021Error..
84. Lindgren T, Ahlm C, Mohamed N, Evander M, Ljunggren HG, Bjorkstrom NK (2011) Longitudinal analysis of the human T cell response during acute hantavirus infection. J Virol 85(19):10252–10260. doi:10.1128/JVI.05548-11.
85. Liu L, Wei Q, Nishiura K, Peng J, Wang H, Midkiff C, Alvarez X, Qin C, Lackner A, Chen Z (2015) Spatiotemporal interplay of severe acute respiratory syndrome coronavirus and respiratory mucosal cells drives viral dissemination in rhesus macaques. Mucosal Immunol. doi:10.1038/mi.2015.127.
86. Luan YY, Yao YM, Xiao XZ, Sheng ZY (2015) Insights into the apoptotic death of immune cells in sepsis. J Interferon Cytokine Res Official J Int Soc Interferon Cytokine Res 35(1):17–22. doi:10.1089/jir.2014.0069.
87. Luczkowiak J, Arribas JR, Gomez S, Jimenez-Yuste V, de la Calle F, Viejo A, Delgado R (2016) Specific neutralizing response in plasma from convalescent patients of Ebola Virus disease against the West Africa Makona variant of Ebola virus. Virus Res 213:224–229. doi:10.1016/j.virusres.2015.12.019.
88. Ludtke A, Ruibal P, Becker-Ziaja B, Rottstegge M, Wozniak DM, Cabeza-Cabrerizo M, Thorenz A, Weller R, Kerber R, Idoyaga J, Magassouba N, Gabriel M, Gunther S, Oestereich L, Munoz-Fontela C (2016) Ebola Virus disease is characterized by Poor activation and reduced levels of circulating CD16+ Monocytes. J Infect Dis 214(Suppl 3):S275–S280. doi:10.1093/infdis/jiw260.
89. MacNeil A, Farnon EC, Wamala J, Okware S, Cannon DL, Reed Z, Towner JS, Tappero JW, Lutwama J, Downing R, Nichol ST, Ksiazek TG, Rollin PE (2010) Proportion of deaths and clinical features in Bundibugyo Ebola virus infection, Uganda. Emerg Infect Dis 16(12):1969–1972. doi:10.3201/eid1612.100627.
90. Mahanty S, Hutchinson K, Agarwal S, McRae M, Rollin PE, Pulendran B (2003) Cutting edge: impairment of dendritic cells and adaptive immunity by Ebola and Lassa viruses. J Immunol 170(6):2797–2801.
91. Mari Saez A, Weiss S, Nowak K, Lapeyre V, Zimmermann F, Dux A, Kuhl HS, Kaba M, Regnaut S, Merkel K, Sachse A, Thiesen U, Villanyi L, Boesch C, Dabrowski PW, Radonic A, Nitsche A, Leendertz SA, Petterson S, Becker S, Krahling V, Couacy-Hymann E, Akoua-Koffi C, Weber N, Schaade L, Fahr J, Borchert M, Gogarten JF, Calvignac-Spencer S, Leendertz FH (2015) Investigating the zoonotic origin of the West African Ebola epidemic. EMBO Mol Med 7(1):17–23. doi:10.15252/emmm.201404792.
92. Martines RB, Ng DL, Greer PW, Rollin PE, Zaki SR (2015) Tissue and cellular tropism, pathology and pathogenesis of Ebola and Marburg viruses. J Pathol 235(2):153–174. doi:10.1002/path.4456.
93. Martinez O, Johnson JC, Honko A, Yen B, Shabman RS, Hensley LE, Olinger GG, Basler CF (2013) Ebola virus exploits a monocyte differentiation program to promote its entry. J Virol 87(7):3801–3814. doi:10.1128/JVI.02695-12.
94. Martini GA (1973) Marburg virus disease. Postgrad Med J 49(574):542–546.
95. Mate SE, Kugelman JR, Nyenswah TG, Ladner JT, Wiley MR, Cordier-Lassalle T, Christie A, Schroth GP, Gross SM, Davies-Wayne GJ, Shinde SA, Murugan R, Sieh SB, Badio M, Fakoli L, Taweh F, de Wit E, van Doremalen N, Munster VJ, Pettitt J, Prieto K, Humrighouse BW, Stroher U, DiClaro JW, Hensley LE, Schoepp RJ, Safronetz D, Fair J, Kuhn JH, Blackley DJ, Laney AS, Williams DE, Lo T, Gasasira A, Nichol ST, Formenty P, Kateh FN, De Cock KM, Bolay F, Sanchez-Lockhart M, Palacios G (2015) Molecular evidence of sexual transmission of Ebola Virus. N Engl J Med 373(25):2448–2454. doi:10.1056/NEJMoa1509773.
96. Mattia JG, Vandy MJ, Chang JC, Platt DE, Dierberg K, Bausch DG, Brooks T, Conteh S, Crozier I, Fowler RA, Kamara AP, Kang C, Mahadevan S, Mansaray Y, Marcell L, McKay G, O’Dempsey T, Parris V, Pinto R, Rangel A, Salam AP, Shantha J, Wolfman V, Yeh S, Chan AK, Mishra S (2016) Early clinical sequelae of Ebola virus disease in Sierra Leone: a cross-sectional study. Lancet Infect Dis 16(3):331–338. doi:10.1016/S1473-3099(15)00489-2.
97. McElroy AK, Erickson BR, Flietstra TD, Rollin PE, Nichol ST, Towner JS, Spiropoulou CF (2014a) Biomarker correlates of survival in pediatric patients with Ebola virus disease. Emerging infectious diseases.
98. McElroy AK, Erickson BR, Flietstra TD, Rollin PE, Nichol ST, Towner JS, Spiropoulou CF (2014b) Ebola hemorrhagic Fever: novel biomarker correlates of clinical outcome. J Infect Dis 210(4):558–566. doi:10.1093/infdis/jiu088.
99. McElroy AK, Akondy RS, Davis CW, Ellebedy AH, Mehta AK, Kraft CS, Lyon GM, Ribner BS, Varkey J, Sidney J, Sette A, Campbell S, Stroher U, Damon I, Nichol ST, Spiropoulou CF, Ahmed R (2015a) Human Ebola virus infection results in substantial immune activation. Proc Natl Acad Sci U S A 112(15):4719–4724. doi:10.1073/pnas.1502619112.
100. McElroy AK, Erickson BR, Flietstra TD, Rollin PE, Towner JS, Nichol ST, Spiropoulou CF (2015b) Von Willebrand factor is elevated in individuals infected with Sudan virus and is associated with adverse clinical outcomes. Viral Immunol 28(1):71–73. doi:10.1089/vim.2014.0072.
101. McElroy AK, Harmon JR, Flietstra TD, Campbell S, Mehta AK, Kraft CS, Lyon MG, Varkey JB, Ribner BS, Kratochvil CJ, Iwen PC, Smith PW, Ahmed R, Nichol ST, Spiropoulou CF (2016) Kinetic analysis of biomarkers in a Cohort of US patients with Ebola Virus disease. Clin Infect Dis Official Publ Infect Dis Soc Am 63(4):460–467. doi:10.1093/cid/ciw334.
102. McNab F, Mayer-Barber K, Sher A, Wack A, O’Garra A (2015) Type I interferons in infectious disease. Nat Rev Immunol 15(2):87–103. doi:10.1038/nri3787.
103. Merad M, Ginhoux F, Collin M (2008) Origin, homeostasis and function of Langerhans cells and other langerin-expressing dendritic cells. Nat Rev Immunol 8(12):935–947. doi:10.1038/nri2455.
104. Mesman AW, de Vries RD, McQuaid S, Duprex WP, de Swart RL, Geijtenbeek TB (2012) A prominent role for DC-SIGN+ dendritic cells in initiation and dissemination of measles virus infection in non-human primates. PLoS ONE 7(12):e49573. doi:10.1371/journal.pone.0049573.
105. Miller JD, van der Most RG, Akondy RS, Glidewell JT, Albott S, Masopust D, Murali-Krishna K, Mahar PL, Edupuganti S, Lalor S, Germon S, Del Rio C, Mulligan MJ, Staprans SI, Altman JD, Feinberg MB, Ahmed R (2008) Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines. Immunity 28(5):710–722. doi:10.1016/j.immuni.2008.02.020.
106. Misasi J, Gilman MS, Kanekiyo M, Gui M, Cagigi A, Mulangu S, Corti D, Ledgerwood JE, Lanzavecchia A, Cunningham J, Muyembe-Tamfun JJ, Baxa U, Graham BS, Xiang Y, Sullivan NJ, McLellan JS (2016) Structural and molecular basis for Ebola virus neutralization by protective human antibodies. Science 351(6279):1343–1346. doi:10.1126/science.aad6117.
107. Mohamadzadeh M, Chen L, Schmaljohn AL (2007) How Ebola and Marburg viruses battle the immune system. Nat Rev Immunol 7(7):556–567. doi:10.1038/nri2098.
108. Mohamadzadeh M, Coberley SS, Olinger GG, Kalina WV, Ruthel G, Fuller CL, Swenson DL, Pratt WD, Kuhns DB, Schmaljohn AL (2006) Activation of triggering receptor expressed on myeloid cells-1 on human neutrophils by marburg and ebola viruses. J Virol 80(14):7235–7244. doi:10.1128/JVI.00543-06.
109. Mupere E, Kaducu OF, Yoti Z (2001) Ebola haemorrhagic fever among hospitalised children and adolescents in northern Uganda: epidemiologic and clinical observations. Afr Health Sci 1(2):60–65.
110. Murin CD, Fusco ML, Bornholdt ZA, Qiu X, Olinger GG, Zeitlin L, Kobinger GP, Ward AB, Saphire EO (2014) Structures of protective antibodies reveal sites of vulnerability on Ebola virus. Proc Natl Acad Sci U S A 111(48):17182–17187. doi:10.1073/pnas.1414164111.
111. Okware SI, Omaswa FG, Zaramba S, Opio A, Lutwama JJ, Kamugisha J, Rwaguma EB, Kagwa P, Lamunu M (2002) An outbreak of Ebola in Uganda. Trop Med Int Health TM & IH 7(12):1068–1075.
112. Olal D, Kuehne AI, Bale S, Halfmann P, Hashiguchi T, Fusco ML, Lee JE, King LB, Kawaoka Y, Dye JM Jr, Saphire EO (2012) Structure of an antibody in complex with its mucin domain linear epitope that is protective against Ebola virus. J Virol 86(5):2809–2816. doi:10.1128/JVI.05549-11.
113. Olinger GG Jr, Pettitt J, Kim D, Working C, Bohorov O, Bratcher B, Hiatt E, Hume SD, Johnson AK, Morton J, Pauly M, Whaley KJ, Lear CM, Biggins JE, Scully C, Hensley L, Zeitlin L (2012) Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques. Proc Natl Acad Sci U S A 109(44):18030–18035. doi:10.1073/pnas.1213709109.
114. Onyango CO, Opoka ML, Ksiazek TG, Formenty P, Ahmed A, Tukei PM, Sang RC, Ofula VO, Konongoi SL, Coldren RL, Grein T, Legros D, Bell M, De Cock KM, Bellini WJ, Towner JS, Nichol ST, Rollin PE (2007) Laboratory diagnosis of Ebola hemorrhagic fever during an outbreak in Yambio, Sudan, 2004. J Infect Dis 196(Suppl 2):S193–198. doi:10.1086/520609.
115. Qin E, Bi J, Zhao M, Wang Y, Guo T, Yan T, Li Z, Sun J, Zhang J, Chen S, Wu Y, Li J, Zhong Y (2015) Clinical Features of Patients With Ebola Virus Disease in Sierra Leone. Clin Infect Dis Official Publ Infect Dis Soc Am 61(4):491–495. doi:10.1093/cid/civ319.
116. Rhein BA, Brouillette RB, Schaack GA, Chiorini JA, Maury W (2016) Characterization of human and murine T-cell immunoglobulin mucin domain 4 (TIM-4) IgV domain residues critical for Ebola Virus Entry. J Virol 90(13):6097–6111. doi:10.1128/JVI.00100-16.
117. Rivera JA, McGuire TC (2005) Equine infectious anemia virus-infected dendritic cells retain antigen presentation capability. Virology 335(2):145–154. doi:10.1016/j.virol.2005.02.013.
118. Roddy P, Thomas SL, Jeffs B, Nascimento Folo P, Pablo Palma P, Moco Henrique B, Villa L, Damiao Machado FP, Bernal O, Jones SM, Strong JE, Feldmann H, Borchert M (2010) Factors associated with Marburg hemorrhagic fever: analysis of patient data from Uige, Angola. J Infect Dis 201(12):1909–1918. doi:10.1086/652748.
119. Rodriguez LL, De Roo A, Guimard Y, Trappier SG, Sanchez A, Bressler D, Williams AJ, Rowe AK, Bertolli J, Khan AS, Ksiazek TG, Peters CJ, Nichol ST (1999) Persistence and genetic stability of Ebola virus during the outbreak in Kikwit, Democratic Republic of the Congo, 1995. J Infect Dis 179(Suppl 1):S170–176. doi:10.1086/514291.
120. Rollin PE, Bausch DG, Sanchez A (2007) Blood chemistry measurements and D-Dimer levels associated with fatal and nonfatal outcomes in humans infected with Sudan Ebola virus. J Infect Dis 196(Suppl 2):S364–371. doi:10.1086/520613.
121. Rowe AK, Bertolli J, Khan AS, Mukunu R, Muyembe-Tamfum JJ, Bressler D, Williams AJ, Peters CJ, Rodriguez L, Feldmann H, Nichol ST, Rollin PE, Ksiazek TG (1999) Clinical, virologic, and immunologic follow-up of convalescent Ebola hemorrhagic fever patients and their household contacts, Kikwit, Democratic Republic of the Congo. Commission de Lutte contre les Epidemies a Kikwit. J Infect Dis 179(Suppl 1):S28–35. doi:10.1086/514318.
122. Ruibal P, Oestereich L, Ludtke A, Becker-Ziaja B, Wozniak DM, Kerber R, Korva M, Cabeza-Cabrerizo M, Bore JA, Koundouno FR, Duraffour S, Weller R, Thorenz A, Cimini E, Viola D, Agrati C, Repits J, Afrough B, Cowley LA, Ngabo D, Hinzmann J, Mertens M, Vitoriano I, Logue CH, Boettcher JP, Pallasch E, Sachse A, Bah A, Nitzsche K, Kuisma E, Michel J, Holm T, Zekeng EG, Garcia-Dorival I, Wolfel R, Stoecker K, Fleischmann E, Strecker T, Di Caro A, Avsic-Zupanc T, Kurth A, Meschi S, Mely S, Newman E, Bocquin A, Kis Z, Kelterbaum A, Molkenthin P, Carletti F, Portmann J, Wolff S, Castilletti C, Schudt G, Fizet A, Ottowell LJ, Herker E, Jacobs T, Kretschmer B, Severi E, Ouedraogo N, Lago M, Negredo A, Franco L, Anda P, Schmiedel S, Kreuels B, Wichmann D, Addo MM, Lohse AW, De Clerck H, Nanclares C, Jonckheere S, Van Herp M, Sprecher A, Xiaojiang G, Carrington M, Miranda O, Castro CM, Gabriel M, Drury P, Formenty P, Diallo B, Koivogui L, Magassouba N, Carroll MW, Gunther S, Munoz-Fontela C (2016) Unique human immune signature of Ebola virus disease in Guinea. Nature 533(7601):100–104. doi:10.1038/nature17949.
123. Sanchez A, Geisbert T, Feldmann H (2007a) Filoviridae: Marburg and Ebola Viruses, vol 1. Fields’ virology, 5th edn. Wolters kluwer/Lippincott Williams & Wilkins, Philadelphia.
124. Sanchez A, Ksiazek TG, Rollin PE, Miranda ME, Trappier SG, Khan AS, Peters CJ, Nichol ST (1999) Detection and molecular characterization of Ebola viruses causing disease in human and nonhuman primates. J Infect Dis 179(Suppl 1):S164–169. doi:10.1086/514282.
125. Sanchez A, Lukwiya M, Bausch D, Mahanty S, Sanchez AJ, Wagoner KD, Rollin PE (2004) Analysis of human peripheral blood samples from fatal and nonfatal cases of Ebola (Sudan) hemorrhagic fever: cellular responses, virus load, and nitric oxide levels. J Virol 78(19):10370–10377. doi:10.1128/JVI.78.19.10370-10377.2004.
126. Sanchez A, Trappier SG, Mahy BW, Peters CJ, Nichol ST (1996) The virion glycoproteins of Ebola viruses are encoded in two reading frames and are expressed through transcriptional editing. Proc Natl Acad Sci U S A 93(8):3602–3607.
127. Sanchez A, Wagoner KE, Rollin PE (2007b) Sequence-based human leukocyte antigen-B typing of patients infected with Ebola virus in Uganda in 2000: identification of alleles associated with fatal and nonfatal disease outcomes. J Infect Dis 196(Suppl 2):S329–336. doi:10.1086/520588.
128. Schaible UE, Kaufmann SH (2007) Malnutrition and infection: complex mechanisms and global impacts. PLoS Med 4(5):e115. doi:10.1371/journal.pmed.0040115.
129. Schieffelin JS, Shaffer JG, Goba A, Gbakie M, Gire SK, Colubri A, Sealfon RS, Kanneh L, Moigboi A, Momoh M, Fullah M, Moses LM, Brown BL, Andersen KG, Winnicki S, Schaffner SF, Park DJ, Yozwiak NL, Jiang PP, Kargbo D, Jalloh S, Fonnie M, Sinnah V, French I, Kovoma A, Kamara FK, Tucker V, Konuwa E, Sellu J, Mustapha I, Foday M, Yillah M, Kanneh F, Saffa S, Massally JL, Boisen ML, Branco LM, Vandi MA, Grant DS, Happi C, Gevao SM, Fletcher TE, Fowler RA, Bausch DG, Sabeti PC, Khan SH, Garry RF, Program KGHLF, Viral Hemorrhagic Fever C, Team WHOCR (2014) Clinical illness and outcomes in patients with Ebola in Sierra Leone. N Engl J Med 371(22):2092–2100. doi:10.1056/NEJMoa1411680.
130. Schmaljohn A, Lewis GK (2016) Cell-targeting antibodies in immunity to Ebola. Pathog Dis 74(4). doi:10.1093/femspd/ftw021.
131. Schuh AJ, Amman BR, Jones ME, Sealy TK, Uebelhoer LS, Spengler JR, Martin BE, Coleman-McCray JA, Nichol ST, Towner JS (2017) Modelling filovirus mainteinance in nature by experimental transmission of Marburg virus between Egyptian rousette bats. Nat Commun 8:14446. doi:10.1038/ncomms14446.
132. Schwartz AJ, Alvarez X, Lackner AA (2002) Distribution and immunophenotype of DC-SIGN-expressing cells in SIV-infected and uninfected macaques. AIDS Res Hum Retroviruses 18(14):1021–1029. doi:10.1089/08892220260235380.
133. Sharma P, Allison JP (2015) Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell 161(2):205–214. doi:10.1016/j.cell.2015.03.030.
134. Simmons G, Reeves JD, Grogan CC, Vandenberghe LH, Baribaud F, Whitbeck JC, Burke E, Buchmeier MJ, Soilleux EJ, Riley JL, Doms RW, Bates P, Pohlmann S (2003) DC-SIGN and DC-SIGNR bind ebola glycoproteins and enhance infection of macrophages and endothelial cells. Virology 305(1):115–123.
135. Smith LM, Hensley LE, Geisbert TW, Johnson J, Stossel A, Honko A, Yen JY, Geisbert J, Paragas J, Fritz E, Olinger G, Young HA, Rubins KH, Karp CL (2013) Interferon-beta therapy prolongs survival in rhesus macaque models of Ebola and Marburg hemorrhagic fever. J Infect Dis 208(2):310–318. doi:10.1093/infdis/jis921.
136. Sobarzo A, Perelman E, Groseth A, Dolnik O, Becker S, Lutwama JJ, Dye JM, Yavelsky V, Lobel L, Marks RS (2012) Profiling the native specific human humoral immune response to Sudan Ebola virus strain Gulu by chemiluminescence enzyme-linked immunosorbent assay. Clin Vaccine Immunol CVI 19(11):1844–1852. doi:10.1128/CVI.00363-12.
137. Sow MS, Etard JF, Baize S, Magassouba N, Faye O, Msellati P, Toure AI, Savane I, Barry M, Delaporte E, Postebogui Study G (2016) New evidence of long-lasting persistence of Ebola Virus genetic material in Semen of survivors. J Infect Dis. doi:10.1093/infdis/jiw078.
138. Sueblinvong V, Johnson DW, Weinstein GL, Connor MJ Jr., Crozier I, Liddell AM, Franch HA, Wall BR, Kalil AC, Feldman M, Lisco SJ, Sevransky JE (2015) Critical care for multiple organ failure secondary to Ebola Virus disease in the United States. Crit Care Med 43(10):2066–2075. doi:10.1097/CCM.0000000000001197.
139. Sundar K, Boesen A, Coico R (2007) Computational prediction and identification of HLA-A2.1-specific Ebola virus CTL epitopes. Virology 360(2):257–263. doi:10.1016/j.virol.2006.09.042.
140. Takada A, Fujioka K, Tsuiji M, Morikawa A, Higashi N, Ebihara H, Kobasa D, Feldmann H, Irimura T, Kawaoka Y (2004) Human macrophage C-type lectin specific for galactose and N-acetylgalactosamine promotes filovirus entry. J Virol 78(6):2943–2947.
141. Tamburini BA, Burchill MA, Kedl RM (2014) Antigen capture and archiving by lymphatic endothelial cells following vaccination or viral infection. Nat Commun 5:3989. doi:10.1038/ncomms4989.
142. Tappe D, Perez-Giron JV, Just-Nubling G, Schuster G, Gomez-Medina S, Gunther S, Munoz-Fontela C, Schmidt-Chanasit J (2016) Sustained elevated cytokine levels during recovery phase of Mayaro Virus infection. Emerg Infect Dis 22(4):750–752. doi:10.3201/eid2204.151502.
143. Team WHOER, Agua-Agum J, Ariyarajah A, Blake IM, Cori A, Donnelly CA, Dorigatti I, Dye C, Eckmanns T, Ferguson NM, Fowler RA, Fraser C, Garske T, Hinsley W, Jombart T, Mills HL, Murthy S, Nedjati Gilani G, Nouvellet P, Pelletier L, Riley S, Schumacher D, Shah A, Van Kerkhove MD (2015) Ebola virus disease among children in West Africa. N Engl J Med 372(13):1274–1277. doi:10.1056/NEJMc1415318.
144. Terajima M, Ennis FA (2011) T cells and pathogenesis of hantavirus cardiopulmonary syndrome and hemorrhagic fever with renal syndrome. Viruses 3(7):1059–1073. doi:10.3390/v3071059.
145. Towner JS, Rollin PE, Bausch DG, Sanchez A, Crary SM, Vincent M, Lee WF, Spiropoulou CF, Ksiazek TG, Lukwiya M, Kaducu F, Downing R, Nichol ST (2004) Rapid diagnosis of Ebola hemorrhagic fever by reverse transcription-PCR in an outbreak setting and assessment of patient viral load as a predictor of outcome. J Virol 78(8):4330–4341.
146. Uyeki TM, Erickson BR, Brown S, McElroy AK, Cannon D, Gibbons A, Sealy T, Kainulainen MH, Schuh AJ, Kraft CS, Mehta AK, Lyon GM III, Varkey JB, Ribner BS, Ellison RT 3rd, Carmody E, Nau GJ, Spiropoulou C, Nichol ST, Stroher U (2016) Ebola Virus persistence in Semen of male survivors. Clin Infect Dis Official Publ Infect Dis Soc Am 62(12):1552–1555. doi:10.1093/cid/ciw202.
147. Uyeki TM, Mehta AK, Davey RT, Jr., Liddell AM, Wolf T, Vetter P, Schmiedel S, Grunewald T, Jacobs M, Arribas JR, Evans L, Hewlett AL, Brantsaeter AB, Ippolito G, Rapp C, Hoepelman AI, Gutman J, Working Group of the USECNoCMoEVDPitUS, Europe (2016) Clinical management of Ebola Virus disease in the United States and Europe. N Engl J Med 374(7):636–646. doi:10.1056/NEJMoa1504874.
148. van Griensven J, Edwards T, de Lamballerie X, Semple MG, Gallian P, Baize S, Horby PW, Raoul H, Magassouba N, Antierens A, Lomas C, Faye O, Sall AA, Fransen K, Buyze J, Ravinetto R, Tiberghien P, Claeys Y, De Crop M, Lynen L, Bah EI, Smith PG, Delamou A, De Weggheleire A, Haba N, Ebola-Tx C (2016) Evaluation of convalescent plasma for Ebola Virus disease in Guinea. N Engl J Med 374(1):33–42. doi:10.1056/NEJMoa1511812.
149. van Paassen J, Bauer MP, Arbous MS, Visser LG, Schmidt-Chanasit J, Schilling S, Olschlager S, Rieger T, Emmerich P, Schmetz C, van de Berkmortel F, van Hoek B, van Burgel ND, Osterhaus AD, Vossen AC, Gunther S, van Dissel JT (2012) Acute liver failure, multiorgan failure, cerebral oedema, and activation of proangiogenic and antiangiogenic factors in a case of Marburg haemorrhagic fever. Lancet Infect Dis 12(8):635–642. doi:10.1016/S1473-3099(12)70018-X.
150. Varkey JB, Shantha JG, Crozier I, Kraft CS, Lyon GM, Mehta AK, Kumar G, Smith JR, Kainulainen MH, Whitmer S, Stroher U, Uyeki TM, Ribner BS, Yeh S (2015) Persistence of Ebola Virus in ocular fluid during convalescence. N Engl J Med 372(25):2423–2427. doi:10.1056/NEJMoa1500306.
151. Villinger F, Rollin PE, Brar SS, Chikkala NF, Winter J, Sundstrom JB, Zaki SR, Swanepoel R, Ansari AA, Peters CJ (1999) Markedly elevated levels of interferon (IFN)-gamma, IFN-alpha, interleukin (IL)-2, IL-10, and tumor necrosis factor-alpha associated with fatal Ebola virus infection. J Infect Dis 179(Suppl 1):S188–191. doi:10.1086/514283.
152. Wahid R, Cannon MJ, Chow M (2005) Dendritic cells and macrophages are productively infected by poliovirus. J Virol 79(1):401–409. doi:10.1128/JVI.79.1.401-409.2005.
153. Wahl-Jensen VM, Afanasieva TA, Seebach J, Stroher U, Feldmann H, Schnittler HJ (2005) Effects of Ebola virus glycoproteins on endothelial cell activation and barrier function. J Virol 79(16):10442–10450. doi:10.1128/JVI.79.16.10442-10450.2005.
154. Wauquier N, Becquart P, Padilla C, Baize S, Leroy EM (2010) Human fatal zaire ebola virus infection is associated with an aberrant innate immunity and with massive lymphocyte apoptosis. PLoS Neglected Trop Dis 4(10). doi:10.1371/journal.pntd.0000837.
155. Weiskopf D, Angelo MA, de Azeredo EL, Sidney J, Greenbaum JA, Fernando AN, Broadwater A, Kolla RV, De Silva AD, de Silva AM, Mattia KA, Doranz BJ, Grey HM, Shresta S, Peters B, Sette A (2013) Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8+ T cells. Proc Natl Acad Sci U S A 110(22):E2046–2053. doi:10.1073/pnas.1305227110.
156. Wherry EJ (2011) T cell exhaustion. Nat Immunol 12(6):492–499.
157. Wilson JA, Hart MK (2001) Protection from Ebola virus mediated by cytotoxic T lymphocytes specific for the viral nucleoprotein. J Virol 75(6):2660–2664. doi:10.1128/JVI.75.6.2660-2664.2001.
158. Wirth JP, Rohner F, Woodruff BA, Chiwile F, Yankson H, Koroma AS, Russel F, Sesay F, Dominguez E, Petry N, Shahab-Ferdows S, de Onis M, Hodges MH (2016) Anemia, micronutrient deficiencies, and Malaria in children and women in Sierra Leone prior to the Ebola outbreak—findings of a cross-sectional study. PLoS ONE 11(5):e0155031. doi:10.1371/journal.pone.0155031.
159. Wolf T, Kann G, Becker S, Stephan C, Brodt HR, de Leuw P, Grunewald T, Vogl T, Kempf VA, Keppler OT, Zacharowski K (2015) Severe Ebola virus disease with vascular leakage and multiorgan failure: treatment of a patient in intensive care. Lancet 385(9976):1428–1435. doi:10.1016/S0140-6736(14)62384-9.
160. Yan T, Mu J, Qin E, Wang Y, Liu L, Wu D, Jia H, Li Z, Guo T, Wang X, Qin Y, Li Y, Chen S, Zhang Y, Zhang J, Wu Y, Wang S, Li J (2015) Clinical characteristics of 154 patients suspected of having Ebola virus disease in the Ebola holding center of Jui Government Hospital in Sierra Leone during the 2014 Ebola outbreak. Eur J Clin Microbiol Infect Dis 34(10):2089–2095. doi:10.1007/s10096-015-2457-z.
161. Yang Z, Delgado R, Xu L, Todd RF, Nabel EG, Sanchez A, Nabel GJ (1998) Distinct cellular interactions of secreted and transmembrane Ebola virus glycoproteins. Science 279(5353):1034–1037.
162. Yang ZY, Duckers HJ, Sullivan NJ, Sanchez A, Nabel EG, Nabel GJ (2000) Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury. Nat Med 6(8):886–889. doi:10.1038/78645.
163. Yen B, Mulder LC, Martinez O, Basler CF (2014) Molecular basis for ebolavirus VP35 suppression of human dendritic cell maturation. J Virol 88(21):12500–12510. doi:10.1128/JVI.02163-14.
164. Yen JY, Garamszegi S, Geisbert JB, Rubins KH, Geisbert TW, Honko A, Xia Y, Connor JH, Hensley LE (2011) Therapeutics of ebola hemorrhagic Fever: whole-genome transcriptional analysis of successful disease mitigation. J Infect Dis 204(Suppl 3):S1043–1052. doi:10.1093/infdis/jir345.
165. Zhang N, Bevan MJ (2011) CD8(+) T cells: foot soldiers of the immune system. Immunity 35(2):161–168. doi:10.1016/j.immuni.2011.07.010.
166. Zhu FC, Hou LH, Li JX, Wu SP, Liu P, Zhang GR, Hu YM, Meng FY, Xu JJ, Tang R, Zhang JL, Wang WJ, Duan L, Chu K, Liang Q, Hu JL, Luo L, Zhu T, Wang JZ, Chen W (2015) Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet 385(9984):2272–2279. doi:10.1016/S0140-6736(15)60553-0.